Antiplatelet therapy in ischemic stroke

Endre Pongrácz, Zoltán Káposzta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Stroke is the third leading cause of death and the leading cause of disability in the developed world. Atherothrombosis is the underlying condition that results in events leading to ischemic stroke and vascular death. Antiplatelet therapy is commonly used for both acute stroke and in secondary prevention. Numerous trials and meta-analyses have left little doubt that antiplatelet therapy effectively reduces stroke risk in patients with prior stroke or transient ischemic attack. Current antiplatelet agents include acetylsalicylic acid, clopidogrel, ticlopidine and extended release dipyridamole with low doses of acetylsalicyclic acid (aspirin). The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient. Recently, the correlation between the laboratory-measurable effect of antiplatelet agents and the clinical effectiveness on the mortality of ischemic stroke and cardiovascular patients has been documented. Due to the side effect of bleeding with different antithrombotic drugs, their future employment will be determined in combination with low dosages of each component. Laboratory-controlled, tailored drug therapy will be needed for long-lasting secondary prevention of ischemic stroke.

Original languageEnglish
Pages (from-to)541-549
Number of pages9
JournalExpert Review of Neurotherapeutics
Volume5
Issue number4
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Stroke
Platelet Aggregation Inhibitors
clopidogrel
Secondary Prevention
Aspirin
Therapeutics
Ticlopidine
Dipyridamole
Transient Ischemic Attack
Blood Vessels
Meta-Analysis
Cause of Death
Myocardial Infarction
Hemorrhage
Drug Therapy
Acids
Mortality
Pharmaceutical Preparations

Keywords

  • Antiplatelet therapy
  • Aspirin resistance
  • Ischemic stroke
  • Secondary prevention

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Antiplatelet therapy in ischemic stroke. / Pongrácz, Endre; Káposzta, Zoltán.

In: Expert Review of Neurotherapeutics, Vol. 5, No. 4, 07.2005, p. 541-549.

Research output: Contribution to journalArticle

@article{77c613f5e1b444bea917e62c345a693b,
title = "Antiplatelet therapy in ischemic stroke",
abstract = "Stroke is the third leading cause of death and the leading cause of disability in the developed world. Atherothrombosis is the underlying condition that results in events leading to ischemic stroke and vascular death. Antiplatelet therapy is commonly used for both acute stroke and in secondary prevention. Numerous trials and meta-analyses have left little doubt that antiplatelet therapy effectively reduces stroke risk in patients with prior stroke or transient ischemic attack. Current antiplatelet agents include acetylsalicylic acid, clopidogrel, ticlopidine and extended release dipyridamole with low doses of acetylsalicyclic acid (aspirin). The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient. Recently, the correlation between the laboratory-measurable effect of antiplatelet agents and the clinical effectiveness on the mortality of ischemic stroke and cardiovascular patients has been documented. Due to the side effect of bleeding with different antithrombotic drugs, their future employment will be determined in combination with low dosages of each component. Laboratory-controlled, tailored drug therapy will be needed for long-lasting secondary prevention of ischemic stroke.",
keywords = "Antiplatelet therapy, Aspirin resistance, Ischemic stroke, Secondary prevention",
author = "Endre Pongr{\'a}cz and Zolt{\'a}n K{\'a}poszta",
year = "2005",
month = "7",
doi = "10.1586/14737175.5.4.541",
language = "English",
volume = "5",
pages = "541--549",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Antiplatelet therapy in ischemic stroke

AU - Pongrácz, Endre

AU - Káposzta, Zoltán

PY - 2005/7

Y1 - 2005/7

N2 - Stroke is the third leading cause of death and the leading cause of disability in the developed world. Atherothrombosis is the underlying condition that results in events leading to ischemic stroke and vascular death. Antiplatelet therapy is commonly used for both acute stroke and in secondary prevention. Numerous trials and meta-analyses have left little doubt that antiplatelet therapy effectively reduces stroke risk in patients with prior stroke or transient ischemic attack. Current antiplatelet agents include acetylsalicylic acid, clopidogrel, ticlopidine and extended release dipyridamole with low doses of acetylsalicyclic acid (aspirin). The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient. Recently, the correlation between the laboratory-measurable effect of antiplatelet agents and the clinical effectiveness on the mortality of ischemic stroke and cardiovascular patients has been documented. Due to the side effect of bleeding with different antithrombotic drugs, their future employment will be determined in combination with low dosages of each component. Laboratory-controlled, tailored drug therapy will be needed for long-lasting secondary prevention of ischemic stroke.

AB - Stroke is the third leading cause of death and the leading cause of disability in the developed world. Atherothrombosis is the underlying condition that results in events leading to ischemic stroke and vascular death. Antiplatelet therapy is commonly used for both acute stroke and in secondary prevention. Numerous trials and meta-analyses have left little doubt that antiplatelet therapy effectively reduces stroke risk in patients with prior stroke or transient ischemic attack. Current antiplatelet agents include acetylsalicylic acid, clopidogrel, ticlopidine and extended release dipyridamole with low doses of acetylsalicyclic acid (aspirin). The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient. Recently, the correlation between the laboratory-measurable effect of antiplatelet agents and the clinical effectiveness on the mortality of ischemic stroke and cardiovascular patients has been documented. Due to the side effect of bleeding with different antithrombotic drugs, their future employment will be determined in combination with low dosages of each component. Laboratory-controlled, tailored drug therapy will be needed for long-lasting secondary prevention of ischemic stroke.

KW - Antiplatelet therapy

KW - Aspirin resistance

KW - Ischemic stroke

KW - Secondary prevention

UR - http://www.scopus.com/inward/record.url?scp=22544484192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22544484192&partnerID=8YFLogxK

U2 - 10.1586/14737175.5.4.541

DO - 10.1586/14737175.5.4.541

M3 - Article

C2 - 16026237

AN - SCOPUS:22544484192

VL - 5

SP - 541

EP - 549

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 4

ER -